Neoadjuvant Radiotherapy Versus Surgery Alone for Stage II/III Mid-low Rectal Cancer With or Without High-risk Factors A Prospective Multicenter Stratified Randomized Trial

被引:27
|
作者
Deng, Xiangbing [1 ]
Liu, Ping [2 ]
Jiang, Dan [3 ]
Wei, Mingtian [1 ]
Wang, Xin [4 ]
Yang, Xuyang [1 ]
Zhang, Yuanchuan [5 ]
Wu, Bing [6 ]
Liu, Yanjun [5 ]
Qiu, Meng [4 ]
Zhuang, Hua [7 ]
Zhou, Zongguang [1 ]
Li, Yunfeng [2 ]
Xu, Feng [4 ]
Wang, Ziqiang [1 ]
机构
[1] Sichuan Univ, West China Hosp, Dept Gastrointestinal Surg, Chengdu, Peoples R China
[2] Kunming Med Univ, Affiliated Hosp 3, Colorectal Canc Clin Res Ctr, Kunming, Yunnan, Peoples R China
[3] Sichuan Univ, West China Hosp, Dept Pathol, Chengdu, Peoples R China
[4] Sichuan Univ, West China Hosp, Dept Abdominal Canc, Canc Ctr, Chengdu, Peoples R China
[5] Third Peoples Hosp Chengdu, Dept Gen Surg, Chengdu, Peoples R China
[6] Sichuan Univ, West China Hosp, Dept Radiol, Chengdu, Peoples R China
[7] Sichuan Univ, West China Hosp, Dept Ultrasound, Chengdu, Peoples R China
关键词
local recurrence; rectal cancer; risk stratification; short-course radiotherapy; total moserectal excision;
D O I
10.1097/SLA.0000000000003649
中图分类号
R61 [外科手术学];
学科分类号
摘要
Objective: The aim of this study was to compare stage II/III rectal cancers with or without high-risk factors, and evaluate the effect of neoadjuvant radiotherapy (NRT) in these 2 cohorts. Background: NRT is often used in stage II/III rectal cancers to improve local control, while not affecting overall survival. However, good-quality surgery without NRT may also achieve good local control in selected patients. Methods: According to risk-stratification criteria and clinical staging, consecutive eligible participants of stage II/III rectal cancer were preoperatively classified into patients with (high-risk) or without (low-risk) high-risk factors. Both groups were respectively randomized to receive either short-course radiotherapy (SCRT) + total mesorectal excision (TME) or TME alone, forming the following 4 groups: high-risk patients with (HiR) or without (HiS) radiation, and low-risk patients with (LoR) or without (LoS) radiation. The primary endpoint was local recurrence. The secondary endpoints included overall survival, disease-free survival, distant recurrence, quality of surgery, and safety (NCT01437514). Results: In total, 401 patients were analyzed. With a median 54 months' follow-up, low-risk patients obtained better 3-year cumulative incidence of local recurrence (2.2% vs 11.0%, P = 0.006), overall survival rate (86.9%vs 76.5%, P = 0.002), disease-free survival rate (87.0% vs 67.9%, P < 0.001), and cumulative incidence of distant recurrence (12.5% vs 29.4%, P < 0.001) than high-risk patients. With regard to 3-year cumulative incidence of local recurrence, no differences were observed between the LoR and LoS groups (1.2% vs 3.0%, P = 0.983) or the HiR and HiS groups (12.9% vs 8.9%, P = 0.483). Conclusions and Relevance: Stratification of stage II/III rectal cancers according to risk factors to more precise subclassifications may result in noteworthy differences in survivals and local pelvic control. An extremely low cumulative incidence of local recurrence and survivals in low-risk patients can be achieved with upfront good quality of surgery alone. This trial, owing to the insufficient power, could not prove the noninferiority of surgery alone, but suggest a discriminative use of NRT according to clinical risk stratification in stage II/III rectal cancer.
引用
收藏
页码:1060 / 1069
页数:10
相关论文
共 50 条
  • [41] INNOVA: Interval or neoadjuvant chemotherapy in rectal cancer-A phase II randomized study comparing interval versus neoadjuvant chemotherapy in magnetic resonance imaging-defined high-risk rectal cancer
    Seshadri, Ramakrishnan Ayloor
    Ganesan, Trivadi S.
    Dhanushkodi, Manikandan
    Arunkumar, M. N.
    Sundersingh, Shirley
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [42] A phase III, multicenter randomized controlled trial of neoadjuvant chemotherapy paclitaxel plus cisplatin versus surgery alone for stage IIA-IIIB esophageal squamous cell carcinoma
    Zheng, Yan
    Li, Yin
    Liu, Xianben
    Zhang, Ruixiang
    Wang, Zongfei
    Sun, Haibo
    Liu, Shilei
    JOURNAL OF THORACIC DISEASE, 2017, 9 (01) : 200 - 204
  • [43] Neoadjuvant FOLFOX 4 versus FOLFOX 4 with Cetuximab versus immediate surgery for high-risk stage II and III colon cancers: a multicentre randomised controlled phase II trial - the PRODIGE 22-ECKINOXE trial
    Karoui, Mehdi
    Rullier, Anne
    Luciani, Alain
    Bonnetain, Franck
    Auriault, Marie-Luce
    Sarran, Antony
    Monges, Genevieve
    Trillaud, Herve
    Le Malicot, Karine
    Leroy, Karen
    Sobhani, Iradj
    Bardier, Armelle
    Moreau, Marie
    Brindel, Isabelle
    Seitz, Jean Francois
    Taieb, Julien
    BMC CANCER, 2015, 15
  • [44] Radiotherapy versus radiotherapy combined with temozolomide in high-risk low-grade gliomas after surgery: study protocol for a randomized controlled clinical trial
    Jingjing Wang
    Ying Wang
    Yan He
    Hui Guan
    Ling He
    Xiaoli Mu
    Xingchen Peng
    Trials, 20
  • [45] Radiotherapy versus radiotherapy combined with temozolomide in high-risk low-grade gliomas after surgery: study protocol for a randomized controlled clinical trial
    Wang, Jingjing
    Wang, Ying
    He, Yan
    Guan, Hui
    He, Ling
    Mu, Xiaoli
    Peng, Xingchen
    TRIALS, 2019, 20 (01)
  • [46] Total neoadjuvant treatment with long-course radiotherapy versus concurrent chemoradiotherapy in local advanced rectal cancer with high risk factors (TNTCRT): A multicenter, randomized, open-label, phase 3 trial.
    Wang, Xin
    Liu, Ping
    Xiao, Yi
    Meng, Wenjian
    Tang, Yuanling
    Zhou, Jitao
    Ding, Pei-Rong
    Ding, Ke-Feng
    Wang, Biao
    Guo, Qing
    Sun, Hao
    Qiu, Jian
    Yu, Yongyang
    Wu, Bing
    Zeng, Hanjiang
    Deng, Xiang-bing
    Jiang, Dan
    Shen, Ya-li
    Zhou, Zongguang
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA3511 - LBA3511
  • [47] Neoadjuvant FOLFOX 4 versus FOLFOX 4 plus cetuximab versus immediate surgery for high-risk stage II and III colon cancers: A phase II multicentre randomised controlled trial (PRODIGE 22)
    Karoui, M.
    Rullier, A.
    Mariette, C.
    Maillard, E.
    Bardier, A.
    Poizat, F.
    Luciani, A.
    Sarran, A.
    Legoux, J-L.
    De Chaisemartin, C.
    Lecaille, C.
    Bouche, O.
    Mauvais, F.
    Brunetti, F.
    Prudhomme, M.
    Seitz, J-F.
    Lepage, C.
    Taieb, J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [48] SHORT-TERM OUTCOMES OF TOTAL NEOADJUVANT TREATMENT (TNT) FOR MRI STRATIFIED HIGH-RISK RECTAL CANCER: A SINGLE-CENTER, SINGLE ARM, PROSPECTIVE PHASE II TRIAL.
    Chen, P.
    Wang, L.
    Sun, T.
    Wu, A.
    DISEASES OF THE COLON & RECTUM, 2020, 63 (06) : E112 - E112
  • [49] Total neoadjuvant treatment for MRI-stratified high-risk rectal cancer: a single-center, single-arm, prospective Phase II trial (PKUCH-R02)
    Chen, Peng-Ju
    Wang, Lin
    Sun, Ting-Ting
    Yao, Yun-Feng
    Peng, Yi-Fan
    Zhao, Jun
    Zhan, Tian-Cheng
    Leng, Jia-Hua
    Cai, Yong
    Li, Yong-Heng
    Zhang, Xiao-Yan
    Sun, Ying-Shi
    Li, Zhong-Wu
    Wang, Wei-Hu
    Wu, Ai-Wen
    GASTROENTEROLOGY REPORT, 2023, 11
  • [50] Präoperative Radiotherapie versus postoperative Radiotherapie nach neoadjuvanter Chemotherapie („NeoRad“) beim Hochrisikomammakarzinom: eine prospektive, randomisierte, internationale multizentrische Phase-III-StudiePreoperative radiotherapy versus postoperative radiotherapy after neoadjuvant chemotherapy (“NeoRad”) in high-risk breast cancer: a prospective randomized international multicenter phase III trial
    Christiane Matuschek
    Danny Jazmati
    David Krug
    Stefanie Corradini
    Tanja Fehm
    Eugen Ruckhäberle
    Thorsten Kühn
    Elmar Stickeler
    Carolin Nestle-Krämling
    Johannes Holtschmidt
    Valentina Nekljudova
    Sibylle Loibl
    Wilfried Budach
    Die Onkologie, 2024, 30 (9) : 840 - 844